Skip to content

Prognosis of Heart Transplanted Patients With Heart Failure

Prognosis of Heart Transplanted Patients With Heart Failure (RE-START): a National Multi-center, Retrospective-prospective, Cohort Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05775432
Acronym
RE-START
Enrollment
1000
Registered
2023-03-20
Start date
2023-04-23
Completion date
2042-12-31
Last updated
2024-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

Heart transplantation, Heart failure, Prognosis

Brief summary

Heart transplantation is the most effective treatment for end-stage heart failure, advanced cardiomyopathy, and complex congenital heart disease with severe heart failure or hypoxia. Several clinical studies have shown significant differences in the prognosis of heart transplantation patients with different etiologies, and post-transplantation complications are an important factor affecting patient survival, and there is still a lack of overall prognostic stratification and extensive clinical studies on risk factors after heart transplantation. Therefore, this study is intended to include patients who underwent heart transplantation for different etiologies of heart failure, collect clinical data and biological samples from patients, and use various techniques to deeply interpret the risk factors affecting the prognosis of heart transplantation patients and construct a prognostic prediction model to provide specific and individualized treatment ideas and theoretical basis for improving the survival rate of patients after heart transplantation.

Interventions

None listed

Sponsors

First Affiliated Hospital Xi'an Jiaotong University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
3 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients with end-stage heart failure presented to our hospital who are evaluated by clinicians and ethically approved for heart transplantation * Individuals whose hearts are donated

Exclusion criteria

* Patients refuse to sign informed consent form

Design outcomes

Primary

MeasureTime frameDescription
Change in the incidence of all-cause deathIn-hospital (an average of 1 month), 1, 2, 3, 5, 10, 15 and 20 years after heart transplantation.Death from any cause in patients after heart transplantation, will be assessed from medical records.

Secondary

MeasureTime frameDescription
Use of advanced life support (ALS)In-hospital (an average of 1 month)Duration of ALS after heart transplantation, will be assessed from medical records.
Incidence of postoperative complicationsIn-hospital (an average of 1 month)Postoperative complications after heart transplantation will be assessed from medical records.
ICU admission timeIn-hospital (an average of 1 month)ICU admission time after heart transplantation, will be assessed from medical records.
Change of cardiac function indexIn-hospital (an average of 1 month).Cardiac functional index after heart transplantation will be assessed by transthoracic echocardiography.

Countries

China

Contacts

Primary ContactGuoliang Li
liguoliang_med@163.com+8613759982523
Backup ContactYang Yan
yangyan3@xjtu.edu.cn+862985323865

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026